Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.
Masanari ItokawaMitsuhiro MiyashitaMakoto AraiTakashi DanKatsuyoshi TakahashiTaro TokunagaKayo IshimotoKazuya ToriumiTomoe IchikawaYasue HoriuchiAkiko KoboriSatoshi UsamiTakeo YoshikawaNaoji AmanoShinsuke WashizukaYuji OkazakiToshio MiyataPublished in: Psychiatry and clinical neurosciences (2017)
High-dose pyridoxamine add-on treatment was, in part, effective for a subpopulation of schizophrenia patients with enhanced carbonyl stress. Further randomized, placebo-controlled trials with careful monitoring will be required to validate the efficacy of high-dose pyridoxamine for these patients.
Keyphrases
- high dose
- placebo controlled
- bipolar disorder
- double blind
- end stage renal disease
- low dose
- chronic kidney disease
- stem cell transplantation
- newly diagnosed
- open label
- squamous cell carcinoma
- peritoneal dialysis
- phase ii
- randomized controlled trial
- prognostic factors
- combination therapy
- patient reported outcomes
- rectal cancer